The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors

• Main Authors: Federico Sottotetti (Author), Elisa Ferraris (Author), Barbara Tagliaferri (Author), Raffaella Palumbo (Author), Erica Quaquarini (Author), Cristina Teragni (Author), Emanuela Balletti (Author), Claudia Leli (Author), Andrea Premoli (Author), Ludovica Mollica (Author), Silvia Puglisi (Author), Silvia Sardi (Author), Alberto Malovini (Author), Paolo Pedrazzoli (Author), Antonio Bernardo (Author)
• Format: Knjiga
• Izdano: BioExcel Publishing Ltd, 2022-09-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Tumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD)....